Treprostinil vs Selexipag: side effects in FDA adverse event reports
At a glance
| Treprostinil | Selexipag | |
|---|---|---|
| Drug class | Prostacycline Vasodilator | Prostacyclin Receptor Agonist |
| Brand names | – | Uptravi, Uptravi Titration Pack |
| FAERS reports | 124,472 | 25,665 |
| Serious | 57% | 75% |
| Death outcome | 14,973 | 4,847 |
| Boxed warning | No | No |
Signals both drugs share
| Reaction | Treprostinil | Selexipag | Label screen (A / B) |
|---|---|---|---|
| Pulmonary arterial hypertension | 4,475 · PRR 74.5 | 1,703 · PRR 108.1 | Likely indication confounding / Likely indication confounding |
| Bendopnoea | 138 · PRR 339.6 | 26 · PRR 116.9 | Not in label — unassessed / Not in label — unassessed |
| Catheter site irritation | 108 · PRR 86.0 | 16 · PRR 43.1 | Not in label — unassessed / Not in label — unassessed |
| Pulmonary hypertensive crisis | 84 · PRR 77.4 | 26 · PRR 88.3 | Likely indication confounding / Likely indication confounding |
Labeled signals distinctive to Treprostinil
- Infusion site pain — n=5,691, PRR 135.7 Labeled adverse reaction
- Infusion site erythema — n=3,287, PRR 110.7 Labeled (related wording)
- Infusion site swelling — n=1,871, PRR 73.3 Labeled (related wording)
- Infusion site infection — n=1,518, PRR 348.1 Labeled adverse reaction
- Infusion site haemorrhage — n=1,402, PRR 128.6 Labeled (related wording)
- Infusion site discharge — n=915, PRR 195.1 Labeled (related wording)
- Infusion site induration — n=651, PRR 142.7 Labeled (related wording)
- Infusion site irritation — n=585, PRR 150.2 Labeled (related wording)
Labeled signals distinctive to Selexipag
- Pain in jaw — n=2,434, PRR 76.7 Labeled (related wording)
- Pulmonary veno-occlusive disease — n=84, PRR 112.1 Labeled adverse reaction
Common questions
Which has more reported side effects, Treprostinil or Selexipag?
Treprostinil has 124,472 FAERS reports and Selexipag 25,665. More reports does not mean more dangerous: volume follows how widely and how long a drug has been used, prescription vs over-the-counter status, and publicity. The seriousness share (57% vs 75%) is a better like-for-like signal of the kind of problems reported.
Which side effects do Treprostinil and Selexipag share?
Both drugs carry disproportionality signals for pulmonary arterial hypertension, bendopnoea, catheter site irritation, pulmonary hypertensive crisis. Shared signals often reflect a shared drug class or the condition both are used for.
Is Treprostinil or Selexipag safer?
FAERS cannot answer that: it has no denominator and no comparator. Use this page to see which risks are already on each label and which signals are unlabeled, then check the prescribing information and your clinician for your situation.
Sources: openFDA FAERS pair statistics (OpenPV build 2026-09-14), FDA labels via openFDA, openFDA count queries for seriousness and deaths. Pair chosen because it is a commonly searched comparison. Generated 2026-10-08.